Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.40 |
| ▸ | ICMT | O60725 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17776309 | 0.87 | CSNK2A1 (0.41) | HDAC1CSNK2A1DGAT1ICMTEPHX2 | |
| SCHEMBL12640254 | 0.86 | HDAC1 (0.46) | HDAC1CSNK2A1ICMTEPHX2GGPS1 | |
| SCHEMBL18768815 | 0.85 | LGALS3 (0.40) | HDAC1CSNK2A1DGAT1EPHX2ALOX5 | |
| SCHEMBL18770918 | 0.83 | DRD2 (0.42) | DGAT1EPHX2 | |
| SCHEMBL17776274 | 0.83 | EPHX2 (0.46) | HDAC1CSNK2A1EPHX2ALOX5 | |
| SCHEMBL17490608 | 0.83 | EPHX2 (0.46) | HDAC1CSNK2A1EPHX2GGPS1 | |
| SCHEMBL13437065 | 0.82 | FOLH1 (0.46) | HDAC1CSNK2A1EPHX2 | |
| SCHEMBL18768813 | 0.82 | EPHX2 (0.51) | HDAC1EPHX2 | |
| SCHEMBL19652456 | 0.81 | DRD2 (0.39) | HDAC1CSNK2A1DGAT1ICMTEPHX2 | |
| SCHEMBL25341129 | 0.81 | DGAT1 (0.54) | DGAT1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | NPPA, NPR1, NPR3 | HDAC1 2067/4885CSNK2A1 2397/4885DGAT1 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.